Drug Trial Radar · NCT06179069
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
339
Planned (sponsor's estimate)
Start
Jan 23, 2024
Primary completion
May 30, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Zai Lab (US) LLC
- First posted
- Dec 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Conditions
- SCLC
Interventions
ZL-1310Drug
Drug: ZL-1310
AtezolizumabDrug
Drug Atezolizumab
CarboplatinDrug
Drug Carboplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities of ZL-1310 as a single agent (Part 1A), in combination with Atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)Time frame: up to 24 months
- Incidence of Treatment Emergent Adverse-Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)Time frame: up to 24 months
- Incidence of Serious Adverse Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)Time frame: up to 24 months
- Incidence of Treatment Emergent Adverse Events of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3) and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
- Incidence of Serious Adverse-Events (SAEs) of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
- Antitumor activity per RECIST v1.1 by investigator's assessment of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
- Objective response rate (ORR) per RECIST v1.1 of ZL-1310 as a single agent (Part 2) and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
- Disease control rate (DCR) per RECIST v1.1 of ZL-1310 in combination with atezolizumabTime frame: up to 24 months
Locations
41 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Withdrawn
Yale Cancer Center
New Haven, Connecticut · Recruiting
Sarah Cannon Research Institute
Sarasota, Florida · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Withdrawn
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Withdrawn
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Withdrawn
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China · Terminated
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Terminated
Jilin Cancer Hospital
Ch’ang-ch’un, Jilin, China · Active not recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Withdrawn
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Withdrawn
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichaun, China · Recruiting
Rabin Medical Center
Petah Tikva, Central District, Israel · Recruiting
The Chaim Sheba Medical Center
Ramat Gan, Central District, Israel · Recruiting
Tel Aviv Sourasky Medical Center Ichilov
Tel Aviv, Tel Aviv, Israel · Recruiting
START Barcelona_HM Nou Delfos
Barcelona, Spain · Recruiting
START MADRID_Hospital Universitario HM Sanchinarro
Madrid, Spain · Recruiting
Hospital Regional Universitario de Malaga - Hospital General H
Málaga, Spain · Recruiting
NEXT Oncology - Hospital Quironsalud Madrid
Pozuelo de Alarcón, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, Barcelona, Spain · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain · Recruiting
Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Valencia, Spain · Recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.